Hospira recalled a single lot of the pain suppressor lidocaine last spring, saying particles of iron oxide had been spotted in some vials. The drugmaker has added another 100,200 vials to its recall for the same reason.
The U.S. supply of saline is taking another hit as Baxter recalls yet more sodium chloride: nearly 140,000 bags more. This time the recall is because of the possibility that some of those bags have mold in them.
Jaguar Animal Health has inked a four-year deal with India's Glenmark Pharmaceuticals to manufacture and supply crofelemer for use in treating diarrhea in companion pets.
Two years ago, Sun Pharma was before the U.S. Supreme Court defending a label for one of its generic drugs against claims that it didn't adequately warn against risks. Now the labels on some of its drugs are creating another kind of problem, leading to a recall of more than 216,000 bottles of drugs.
McKesson started its international expansion into drug wholesaling last year when it bought Germany-based Celesio. It then sealed a deal this summer in the U.K., and now it is extending its supply chain with another M&A move in the two Irelands.
GlaxoSmithKline set up a dermatology manufacturing center of excellence in the U.K. several years ago. But its manufacturing of its Bactroban products has proven to be less than excellent of late, leading to the recall of more than a quarter of a million tubes of antibiotic cream that may be contaminated.
Sun Pharmaceutical Industries has picked up two manufacturing sites with its buyout of GlaxoSmithKline's opiates business in Australia, becoming one of three companies globally with a "farm-to-market" opiate business, giving it direct access to poppy crops in Tasmania, where most of the raw materials for opiates are produced.
The Indian Directorate of Revenue Intelligence arrested 6 people, including the owners of three pharmaceutical companies, for possession and distribution of pseudoephedrine.
Hemispherx Biopharma has had a somewhat rocky relationship with both the FDA and the Street. But with a manufacturing upgrade complete and a distribution agreement in hand, it expects to return to the market its only approved product after a 7-year hiatus.
The weeklong production hiatus at a GlaxoSmithKline plant in the U.S. is over. The British drugmaker has resumed making products at its plant in North Carolina that it closed a week ago after routine testing detected the bacteria for Legionnaires' disease in two cooling towers at the site.